Literature DB >> 11239496

Determination of in vivo adducts of disulfiram with mitochondrial aldehyde dehydrogenase.

M L Shen1, K L Johnson, D C Mays, J J Lipsky, S Naylor.   

Abstract

Extensive use for disulfiram (DSF) has been found in the aversion therapy treatment of recovering alcoholics. Although it is known to irreversibly inhibit hepatic aldehyde dehydrogenase (ALDH), the specific mechanism of in vivo inhibition of the enzyme by the drug has not been determined yet. We have demonstrated in this report a novel, but simple and rapid method for structurally characterizing in vivo derived protein-drug adducts by linking on-line sample processing to HPLC-electrospray ionization mass spectrometry (HPLC-MS) and HPLC-tandem mass spectrometry (HPLC-MS/MS). Employing this approach, rats were administered DSF, and their liver mitochondria were isolated and solubilized. Both native and in vivo DSF-treated mitochondrial ALDH (mALDH) were purified in one step with an affinity cartridge. The in vivo DSF-treated mALDH showed 77% inhibition in enzyme activity as compared with that of the control. Subsequently, the control and DSF-inhibited mALDH were both subjected to HPLC-MS analyses. We were able to detect two adducts on DSF-inhibited mALDH, as indicated by the mass increases of approximately 71 and approximately 100 Da. To unequivocally determine the site and structure of these adducts, on-line pepsin digestion-HPLC-MS and HPLC-MS/MS were performed. We observed two new peptides at MH(+) = 973.7 and MH(+) = 1001.8 in the pepsin digestion of DSF-inhibited enzyme. These two peptides were subsequently subjected to HPLC-MS/MS for sequence determination. Both peptides possessed the sequence FNQGQC(301)C(302)C(303), derived from the enzyme active site region, and were modified at Cys(302) by N-ethylcarbamoyl (+71 Da) and N-diethylcarbamoyl (+99 Da) adducts. These findings indicated that N-dealkylation may be an important step in DSF metabolism, and that the inhibition of ALDH occurred by carbamoylation caused by one of the DSF metabolites, most likely S-methyl-N,N-diethylthiocarbamoyl sulfoxide (MeDTC-SO). Finally, there was no evidence of the presence of an intramolecule disulfide bridge modification on the peptide FNQGQCCC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11239496     DOI: 10.1016/s0006-2952(00)00586-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

1.  A novel dithiocarbamate analogue with potentially decreased ALDH inhibition has copper-dependent proteasome-inhibitory and apoptosis-inducing activity in human breast cancer cells.

Authors:  Fei Wang; Shumei Zhai; Xiaojun Liu; Liwen Li; Shirley Wu; Q Ping Dou; Bing Yan
Journal:  Cancer Lett       Date:  2010-10-29       Impact factor: 8.679

2.  Inhibition of the Aldehyde Dehydrogenase 1/2 Family by Psoralen and Coumarin Derivatives.

Authors:  Cameron D Buchman; Thomas D Hurley
Journal:  J Med Chem       Date:  2017-03-06       Impact factor: 7.446

3.  Electrophilic adduction of ubiquitin activating enzyme E1 by N,N-diethyldithiocarbamate inhibits ubiquitin activation and is accompanied by striatal injury in the rat.

Authors:  Olga M Viquez; Samuel W Caito; W Hayes McDonald; David B Friedman; William M Valentine
Journal:  Chem Res Toxicol       Date:  2012-08-22       Impact factor: 3.739

4.  Disulfiram-based disulfides as narrow-spectrum antibacterial agents.

Authors:  Jordan G Sheppard; Keely R Frazier; Pushkar Saralkar; Mohammad F Hossain; Werner J Geldenhuys; Timothy E Long
Journal:  Bioorg Med Chem Lett       Date:  2018-03-10       Impact factor: 2.823

Review 5.  Gasdermin D (GSDMD) as a new target for the treatment of infection.

Authors:  Ankit Pandeya; Lan Li; Zhenyu Li; Yinan Wei
Journal:  Medchemcomm       Date:  2019-04-04       Impact factor: 3.597

Review 6.  Targeting aldehyde dehydrogenase 2: new therapeutic opportunities.

Authors:  Che-Hong Chen; Julio Cesar Batista Ferreira; Eric R Gross; Daria Mochly-Rosen
Journal:  Physiol Rev       Date:  2014-01       Impact factor: 37.312

7.  Inhibition of mitochondrial aldehyde dehydrogenase by nitric oxide-mediated S-nitrosylation.

Authors:  Kwan-Hoon Moon; Bong-Jo Kim; Byoung J Song
Journal:  FEBS Lett       Date:  2005-10-11       Impact factor: 4.124

8.  Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches.

Authors:  Yen Low; Takeki Uehara; Yohsuke Minowa; Hiroshi Yamada; Yasuo Ohno; Tetsuro Urushidani; Alexander Sedykh; Eugene Muratov; Viktor Kuz'min; Denis Fourches; Hao Zhu; Ivan Rusyn; Alexander Tropsha
Journal:  Chem Res Toxicol       Date:  2011-07-21       Impact factor: 3.739

Review 9.  Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application.

Authors:  Vindhya Koppaka; David C Thompson; Ying Chen; Manuel Ellermann; Kyriacos C Nicolaou; Risto O Juvonen; Dennis Petersen; Richard A Deitrich; Thomas D Hurley; Vasilis Vasiliou
Journal:  Pharmacol Rev       Date:  2012-04-27       Impact factor: 25.468

10.  Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors.

Authors:  Yan Chen; Jin-Yi Zhu; Kwon Ho Hong; David C Mikles; Gunda I Georg; Alex S Goldstein; John K Amory; Ernst Schönbrunn
Journal:  ACS Chem Biol       Date:  2018-01-03       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.